Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Protocol Number:  BTG-001653 -01 
Protocol Short Title:  KNOCOUT PE  
Protocol Name:  Retrospective and prospective international E KoSoNic® registry Of 
the treatment and Clinical OUT comes of patients with Pulmonary 
Embolism  
Sponsor:  EKOS Corporation , a BTG International group company  
11911 North Creek Parkway S.  
Bothell, WA 98011 , USA  
Coordinating  
Principal Investigator:  Keith Sterling, MD  
Inova Alexandria Hospital  
4320 Seminary Road  
Alexandria, VA 22304, USA  
Phone: +1.703.504.7950  
E-mail: keithmsterling@gmail.com   
Medical Monitor:  Simon Hogan, MD  
Provensis Ltd, a BTG International group company  
Lakeview, Riverside Way, Watchmoor Park  
Camberley Surrey, GU15 3YL, UK  
Phone: +44.1276.902.020  
E-mail: Simon.Hogan@btgplc.com  
Investigational 
Product  (IP) EkoSonic® Endovascular System (EKOS)  
Clinicaltrials.gov 
identifier  [STUDY_ID_REMOVED]  
EudraCT Number  2018 -001235 -46 
This document is the confidential property of Sponsor. No part of it may be transmitted, reproduced, published, or 
used by other persons without prior written permission.  
 
 
VERSION 
NUMBER  APPROVAL 
DATE  BRIEF DESCRIPTION OF CHANGES  
1.0 22-Nov-2017  Initial Release . 
1.1 1-Dec-2017  Protocol amended to increase number of sites from 50 to 100.  
1.2 4-Jan-2018 Protocol amended to include electronic patient reported 
outcomes.  
2.0 9-May-2018  Protocol amended to modify eligibility criteria, clarify 
assessments , and time points for follow up . Added details of 
planned analysis.   
2.0.EMEA  27-Aug-2018  Removal of appendices ; addition of OPTALYSE PE manuscript 
reference; consistency in device name; more inclusive 
regulatory focus.  
2.1.EMEA  19-Oct-2017  Removal of r -tPA; change to physician -specified fluid to bring in 
alignment with IFU.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Registry  Contacts  
Steering Committee  Principal Investigators listed below, and,  
 
Samuel Z. Goldhaber, MD  
Brigham and Women’s Hospital  
75 Francis Street  
Boston, MA  02115, USA  
Phone: +1 857 307 1932  
E-mail: sgoldhaber@partners.org  
 
Stavros V. Konstantinides, MD, PhD, FESC, FRCP(Glasg)  
Center for Thrombosis and Hemostasis (CTH)  
Johannes Gutenberg University Mainz  
Langenbeckstr. 1, Bldg. 403  
55131 Mainz, Germany  
Phone: +49 6131 17 6255  
Fax: +49 6131 17 3456  
E-mail: stavros.konstantinides@unimedizin -mainz.de  
 
Nicolas Meneveau, MD, PhD  
CHU Besançon  
3 Boulevard Alexandre Fleming  
25030 Besançon, France  
E-mail: nicolas.meneveau@univ -fcomte.fr  
 
Victor F. Tapson, MD, FCCP, FRCP  
Pulmonary Critical Care Medicine   
Cedars -Sinai  
8536 Wilshire Blvd., Suite 201  
Los Angeles, CA 90211, USA  
E-mail: victor.tapson@cshs.org  
 
 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Principal Investigators  Prospective US:  
Keith Sterling, MD  
Inova Alexandria Hospital  
4320 Seminary Road  
Alexandria, VA 22304, USA  
Phone: +1 703 504 7950  
E-mail: keithmsterling@gmail.com   
 
Prospective E urope : 
Nils Kucher, MD  
University Clinic of Angiology  
University Hospital Zurich  
8091  Zurich , Switzerland  
E-mail: nils.kucher@u sz.ch  
 
Retrospective Acute:  
Robert  Maholic, DO  
UPMC Hamot  
201 State Street  
Erie, PA 16550, USA  
Phone: +1 814 456 8980  
E-mail: maholicrl@upmc.edu   
 
Retrospective Long -term: 
Mahir Elder, MD  
Detroit Medical Center  
3990 John Road Ste. 9370  
Detroit, MI 48201, USA  
Phone: +1 313 993 7777  
E-mail: melder@dmc.org  
 
Special Assessments – Echocardiography:  
Gregory Piazza, MD, MS  
Brigham and Women’s Hospital  
75 Francis Street  
Boston, MA  02115, USA  
Phone: +1 617 732 6984  
E-Mail: gpiazza@partners.org  
 
Integrated Bedside Assessments:  
Andrew SP Sharp, MD  
Department of Cardiology  
Royal Devon and Exeter Hospital and Univers ity of Exeter  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Barrack Road, Exeter  EX2 5DW, UK  
Phone 0044 1392 403990  
E-mail: andrew.sharp5@nhs.net  
 
High Risk Populations : 
Noah Jones, MD  
Mount Carmel Health System  
85 McNaughten Road, Suite 300  
Columbus, OH 4 3213, USA  
Phone: +1 703 220 8103  
E-mail: noahj4@gmail.com  
Registry Management  Leslie Cass  
EKOS Corporation, a BTG International group company  
11911 North Creek Parkway S.  
Bothell, WA  98011 -8809, USA  
P: +1 425 415 3113  
F: +1 425 415 3107  
M: +1 206 641 4529  
E-mail:  Leslie.Cass@gmail.com   
 
Timothy Keo  
EKOS Corporation, a BTG International group company  
11911 North Creek Parkway S.  
Bothell, WA  98011 -8809, USA  
P: +1 425 415 3113  
F: +1 425 415 3107  
M: +1 562 508 7301  
E-mail:  Timothy.Keo@btgplc.com   
EDC Provider/Support  DATATRAK International Inc.  
5900 Landerbrook Dr., Suite 170  
Mayfield Heights, OH 44124, USA  
 
  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
PROTOCOL APPROVAL & RELEASE SIGNATURE PAGE  
Protocol Number:  BTG-001653 -01 
Protocol Short Title:  KNOCOUT PE  
Protocol Name:  Retrospective and prospective international E KoSoNic® registry 
study Of the treatment and Clinical OUT comes of patients with 
Pulmonary Embolism  
Protocol Version:  2.1.EMEA  
Protocol Approval 
Date:  19-Oct-2018  
The above -referenced protocol was reviewed and approved for release by the following:  
 
Approver   
Signature   
Date (DD/MMM/YYYY)  
Coordinating  Principal 
Investigator    
Sponsor: VP, Clinical 
Development    
Sponsor: Study Manager    
Sponsor: Project Physician    
Sponsor: Statistician    
   
  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
INVESTIGATOR PROTOCOL REVIEW STATEMENT  
Protocol Number:  BTG-001653 -01 
Protocol Short Title:  KNOCOUT PE  
Protocol Name:  Retrospective and prospective international E KoSoNic® registry 
study Of the treatment and Clinical OUT comes of patients with 
Pulmonary Embolism  
Protocol Version:  2.1.EMEA  
Protocol Approval 
Date:  19-Oct-2018  
The investigational  site Principal Investigator (undersigned) hereby declares that he/she has 
read this protocol and agrees to its contents.  
The undersigned confirms that the registry  will be conducted and documented in accordance 
with the Declaration of Helsinki, th is proto col, standards of Good Clinical Practice, applicable 
laws and regulatory requirements specified in the protocol, and the stipulations of the Clinical 
Trial Agreement . 
By written consent to this protocol , the Principal I nvestigator agre es to the above and to fully 
cooperate with all monitoring and audits in relation to this registry  by allowing direct access to all 
documentation, including source data, by authorized individuals representing EKOS Corporation , 
BTG International , the relevant  institutional  review board /ethics committee  (IRB/EC) and/or by 
regulatory authorities.  
 
Investigator Name (please print):    _________________________________________  
 
Investigator Signature:   _________________________________________  
 
Date (DD/MMM/YYYY):     _________ ________________________________  
 
 
  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
TABLE OF CONTENTS & LIST  OF TABLES  
Registry Contacts  ________________________________ _____________________  2 
PROTOCOL APPROVAL & RELEASE SIGNATURE PAGE  ____________________  5 
INVESTIGATOR PROTOCOL REVIEW STATEMENT  _________________________  6 
TABLE OF CONTENTS & LIST OF TABLES  ________________________________  7 
1. TERMS, ACRONYMS, ABREVIATIONS ________________________________  10 
2. PROTOCOL SYNOPSIS  ________________________________ ____________  12 
3. SCHED ULE OF REGISTRY ASSESSMENTS – PROSPECTIVE  _____________  16 
4. BACKGROUND ________________________________ ___________________  17 
4.1 Pulmonary Embolism (PE)  ________________________________ ____________  17 
4.2 EkoSonic® Endovascular System (EKOS)  Product Description  ______________  18 
4.2.1 EKOS Intended Use  ________________________________ ______________________  18 
4.2.2 EKOS Description  ________________________________ ________________________  18 
4.2.3 EKOS Regulatory Status  ________________________________ ___________________  19 
4.3 EKOS Clinical Summary in Pulmonary Embolism  _________________________  19 
5. REGISTRY OBJECTIVE AND PURPOSE  ______________________________  20 
5.1 Objectives  ________________________________ __________________________  20 
5.2 Design  ________________________________ _____________________________  20 
5.3 Outcome Measures  ________________________________ __________________  21 
6. SUBJECT SELECTION  ________________________________ _____________  21 
6.1 Registry Population  ________________________________ __________________  21 
6.2 Subject Selection  ________________________________ ____________________  22 
6.2.1 Inclusion Criteria  ________________________________ _________________________  22 
6.2.2 Exclusion Criteria  ________________________________ ________________________  22 
6.3 Subject Completion  ________________________________ __________________  22 
6.4 Withdrawal  ________________________________ __________________________  22 
7. CASE DATA COLLECTION – RETROSPECTIVE  ________________________  23 
7.1 Protected Health Information (PHI) Authorization  Waiver  __________________  23 
8. MEASUREMENTS – RETROSPECTIVE  _______________________________  23 
8.1 Screening/Baseline  ________________________________ __________________  23 
8.2 Procedure  ________________________________ __________________________  23 
8.3 Post -Procedure  ________________________________ ______________________  24 
8.4 Long T erm Health Data  ________________________________ _______________  24 
9. TREATMENT OF SUBJECTS - PROSPECTIVE  _________________________  24 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
9.1 EkoSonic® Endovascular System (EKOS)  ________________________________  24 
9.1.1 APT Procedure  ________________________________ __________________________  24 
9.1.2 Post-treatment Management  ________________________________ ________________  25 
9.1.3 Duration of Treatment and Follow -up ________________________________ _________  25 
9.1.4 Adjunctive Interventions  ________________________________ ___________________  25 
10. MEASUREMENTS AND EVALUATIONS - PROSPECTIVE  _______________  25 
10.1 Screening/Baseline (Day -1) ________________________________ ___________  25 
10.2 Procedure Visit (Day 0)  ________________________________ _______________  26 
10.3 Post Procedure Assessments ________________________________ __________  26 
10.4 Follow -Up ________________________________ __________________________  26 
11. Evaluations  ________________________________ ____________________  27 
11.1 Informed Consent Process  ________________________________ ____________  27 
11.2 Eligibility Review  ________________________________ ____________________  27 
11.3 Assignment of Subject Identification Number  ____________________________  27 
11.4 Demographics  ________________________________ _______________________  28 
11.5 Physical Examination ________________________________ _________________  28 
11.6 Vital Signs  ________________________________ __________________________  28 
11.7 Anticoagulation and Concomitant Medications  ___________________________  28 
11.8 Quality of Life Assessments: PEmb -QoL and EQ -5D-5L ____________________  28 
11.9 Integrated Bedside Assessment  ________________________________ ________  28 
12. SAFETY REPORTING  ________________________________ ____________  29 
12.1 Definitions  ________________________________ __________________________  29 
12.1.1  Adverse Event  ________________________________ _________________________  29 
12.1.2  Serious Adverse Event (SAE)  ________________________________ _____________  29 
12.1.3  Unexpected Ad verse Event  ________________________________ _______________  30 
12.1.4  Pre-Existing Medical Condition  ________________________________ ____________  30 
12.1.5  Device Failures and Malfunctions  ________________________________ __________  30 
12.1.6  Major Bleeding  ________________________________ ________________________  30 
12.2 Reporting Requirements  ________________________________ ______________  30 
13. STATISTICAL CONSIDERATIONS  ________________________________ __ 31 
13.1 Statistical Analysis  ________________________________ ___________________  31 
13.2 Determination of Sample Size  ________________________________ __________  31 
13.3 Analysis Populations  ________________________________ _________________  31 
13.4 Patient Disposition  ________________________________ ___________________  32 
13.5 Baseline and Demographics Characteristics  _____________________________  32 
13.6 Measurement of APT treatment  ________________________________ ________  32 
13.7 Efficacy Outcome Measures Analyses  ________________________________ __ 32 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
13.8 Additional Outcome Analyses  ________________________________ _________  32 
13.9 Safety Analyses  ________________________________ _____________________  32 
13.10  Interim Analysis  ________________________________ _____________________  33 
13.11  Handling of Missing Data  ________________________________ _____________  33 
14. DATA MANAGEMENT ________________________________ ____________  33 
15. LEGA L/ETHICS AND ADMINISTRATIVE PROCEDURES  ________________  33 
15.1 Good Clinical Practice/Regulatory Compliance  ___________________________  33 
15.2 Site and Investigator Qualification  ________________________________ ______  34 
15.2.1  Investigator Curriculum Vitae (CV)  ________________________________ _________  34 
15.2.2  Statement of Investigator  ________________________________ _________________  34 
15.3 IRB/EC Protocol Approval  ________________________________ _____________  34 
15.4 Informed Consent – Ethical Compliance  ________________________________ _ 34 
15.5 Subject Privacy and Confidentiality  ________________________________ _____  35 
15.6 Monitoring  ________________________________ __________________________  35 
15.7 Modification of the Protocol  ________________________________ ___________  36 
15.8 Suspension or Termination of Registry  ________________________________ __ 36 
15.9 Protocol Deviations/Violations  ________________________________ _________  36 
15.10  Recording, Access to and Retention of Source Data  _______________________  36 
15.11  Final Data  ________________________________ ___________________________  37 
15.12  Publications  ________________________________ ________________________  37 
15.13  Audit/Inspections  ________________________________ ____________________  37 
LIST OF TABLES  
Table 1: SCHEDULE OF REGISTRY ASSESSMENTS – PROSPECTIVE  
 
  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
1. TERMS , ACRONYMS, ABREVIATIONS  
The following abbreviations and specialist terms are used in this protocol.  
AE Adverse event  
APT  Acoustic Pulse Thrombolysis  
aPTT  Activated partial thromboplastin time  
BNP Brain natriuretic peptide  
CE European Conformity  
CFR Code of Federal Regulation  
CRA  Clinical research associate  
CTA Computed tomography angiography  
CTEPH  Chronic thromboembolic pulmonary hypertension  
CV Curriculum vitae  
DM Data management  
DMP  Data management plan  
DVT Deep vein thrombosis  
eCRF  Electronic case report form  
EDC  Electronic data capture  
EP Efficacy population  
ePRO  Electronic  Patient Reported Outcomes  
EQ-5D-5L Euroqol five dimension five level questionnaire  
FDA Food and Drug Administration  
FPI Full prescribing information  
GCP  Good clinical practice  
Hct Hematocrit  
Hgb Hemoglobin  
HIPAA  Health Information Portability and Accountability Act  
ICF Informed consent form  
ICH Intracranial hemorrhage  
ICU Intensive care unit  
ID Identification  
IDDC  Intelligent Drug Delivery Catheter  
IFU Instructions for Use  
INR International normalized ratio  
IP Investigational product  
IRB/EC Institutional review board /ethics committee  
IVC Inferior vena cava  
LV Left ventricular  
MHz Megahertz  
MSD  MicroS onic device  
PE Pulmonary embolism  
PEmb -QOL  Pulmonary Embolism Quality of Life  
PHI Protected health information  
PT Partial thromboplastin time  
Pts Patients  
QOL  Quality of Life  
r-tPA Recombinant tissue plasminogen activator  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
RV Right ventricular  
RVSP  Right ventricular systolic pressure  
SAE Serious adverse event  
SAP Statistical analysis plan  
SoC Standard of c are 
SP Safety population  
sPESI  Simplified pulmonary embolism severity index  
SpO 2 Peripheral capillary oxygen saturation  
SvO2  Mixed venous oxygen  saturation  
TAPSE  Tricuspid annular plane systolic excursion  
U.K. United K ingdom  
U.S. United S tates  
VTE Venous thromboembolism  
  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
2. PROTOCOL SYNOPSIS  
Protocol Number  BTG-001163 -01 
Protocol Short Title KNOCOUT PE  
Protocol Title  Retrospective and prospective international E KoSoNic® registry 
study Of the treatment and Clinical OUT comes of patients with 
Pulmonary Embolism  
Intervention  Device: EkoSonic® Endovascular System (EKOS) employs high 
frequen cy (2 -3 MHz), low power ultrasound to facilitate the 
delivery of physician -specified  fluids , including thrombolytics,  in 
the pulmonary arteries.  
 
Acoustic Pulse Thrombolysis (APT) Procedure: The clinical use of 
the EKOS  device  in combination with physician -specified fluids. 
Type of Protocol  International Registry  
Trial Objectives  • To understand the APT treatment protocol used as SoC 
across institutions and document changes in practice 
following the OPTALYSE PE study results  
• To des cribe the effects of  varied  APT protocols on long -term 
patient outcomes  
Outcome Measures  1. Change in the ratio of the measurement of the right 
ventricular to left ventricular diameter s (RV/LV) as measured 
on echocardiogram or computed tomography angiography  
(CTA)  from baseline to  between  24 – 48 hours  (hr) after the 
start of the APT procedure  (matched pairs as available) .  
2. Diagnosis of pulmonary hypertension  defined as  mean 
pulmonary artery pressure greater than 25mm Hg  by 
echocardiogram  that persists at least 3 months after PE 
diagnosis   
3. Frequency  and safety outcomes  of adjunctive therapies  post 
APT procedure during  hospitalization  
4. Number of patients with non or partial response to other 
interventional procedures prior to APT procedure for index PE  
5. Frequency and severity of s erious adverse experiences  (SAE)  
related to  EKOS  or procedure , major bleeding, or venous 
thromboembolic disease (VTE) during index hospitalization  
and during first 12 months  post-APT procedure  
6. All-cause mortality during first 12 months  post-APT procedure   
7. Recurrent symptomatic PE, PE related death, hemodynamic 
collapse  at 30 days  (composite measure)  
8. Healthcare utilization during hospitalization:  
a. Time from hospital admission to ICU  discharge  
b. Time from hospital admission to discharge  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
9. Quality of life (QOL) as measured by the Pulmonary 
Embolism Quality of Life (PEmb -QOL) and  EuroQol five 
dimension five level questionnaire  (EQ-5D-5L) at 3 month and 
12 month  post-hospitalization follow -up visits  
10. IVC filter placement (measured by number of occurrences)  
Trial Duration  RETROSPECTIVE  
Data collection  is expected to  occur over a 6 month period  at 
each site   
 
PROSPECTIVE  
Enrollment will take place over approximately a 24 month period. 
For each subject, the ir participation in the  registry lasts 12 
months.  
Trial Design  A multi -center retrospective and prospective registry of the APT 
treatment of patients (pts) with submassive (Intermediate -High 
Risk) and massive (High Risk ) PE. The re trospective portion of 
the registry  will consist of consecutive  patients  treated  with APT 
between  January  1, 2014  and one year prior to date of site 
activation . The pro spective portion of the registry  will collect data 
for pts diagnosed and risk -stratified and treated with APT 
procedure. Pts will be followed for 12 months.  
 
Intermediate -High Risk PE will be defined by evidence of RV 
dysfunction (RV/LV > 1.0), hemodynamic stability (normal 
systemic arte rial blood pressure >90 mmHg), and  troponin  
elevation . 
 
High Risk PE  will be defined with  hemodynamic instability 
(normal systemic arterial blood pressure <90 mm Hg and/or use 
of vasopressors)  
Number of Patients  RETROSPECTIVE  
Up to  1000 evaluable cases  
 
PROSPECTIVE  
Up to 550 consented patients to yield 500 evaluable patients  
Number & Location of 
Sites  Up to 100  sites geographically distributed throughout North 
America, E urope , and Asia  
Eligibility Criteria  RETROSPECTIVE  
Inclusion Criteria  
1. Treated with APT procedure between  January  1, 2014  
and one year prior to date of site activation  
2. RV/LV > 1.0 from  diagnostic  CTA or echocardiogram  
3. PE symptom duration < 14 days  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
4. Troponin elevation  
 
Exclusion Criteria  
5. Enrollment into the OPTALYSE PE study  
 
PROSPECTIVE  
Inclusion Criteria  
1. Male or female > 18 years of age and < 80 years of age  
2. RV/LV > 1.0 from diagnostic CTA  or echocardiogram  
3. PE symptom duration < 14 days  
4. Troponin elevation  
5. Signed informed consent obtained from subject or legally 
authorized representative  
6. Investigator has selec ted EKOS to treat patient with 
massive or submassive PE 
Exclusion Criteria  
7. Clinician deems the subject high -risk for catastrophic 
bleeding  
8. Life expectancy < one year  
Sample Size 
Justification  The aim of the registry is to collect observational data on 
standard of care APT treatment. The sample size is calculated 
from the expected enrollment per site based on estimate d 
cases per physician across total number of sites . For 
retrospective cases, up to 1000 cases will be collected to 
capture details of PE treatment with EKOS from the time it 
became commercially available to the time the site was 
activated. For prospective, up to 500 patients will be treated to 
collect data on current EKOS use at up to 100 sites.  
Statistical Methods  Patients will be analyzed according to the APT treatment protocol 
they received ( i.e. duration of treatment and dose, type of fluid 
received ). Frequency of use of each of the APT treatment 
protocols before and after OPTALYSE PE results were made 
public will be summarized and compared using fisher’s exact test.  
Each outcome measure will be summarized for the full registry 
population as  well as separately by the different APT treatment 
protocols, including 95% confidence intervals. Additionally, 
outcome measures will be summarized by the following 
subgroups: submassive and massive PE,  each  region,  and by 
the retrospective  and prospective  portions of the registry .  
Registry Procedures  See section 3. SCHEDULE OF REGISTRY ASSESSMENTS – 
PROSPECTIVE below  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1.EMEA (19-Oct-2018)   
   
  
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Registry Follow -up 
Visits  For prospective subjects, patients should be followed  per 
Investigator’s standard of care (SoC) . Data will be collected for 
any echocardiograms  and CT As completed  throughout the 12 
month follow -up period . At minimum,  a health status check 
should be performed at 3 and 12  months . An on-site visit with 
echocardiogram is recommended at 3 months for patients with 
abnor mal echocardiogram post -treatment for evaluation of 
chronic pulmonary hypertension, and at 12 months  for all 
patients . Safety data should be reported through 12 months  
post-index procedure . For retrospective cases , long term health  
data will be collected as available  for up to 12 months  post-
index treatment .   
Treatment  Subjects scheduled for treatment with  EKOS  will be  treated as 
prescribed by the Investigator  SoC for treating PE and in 
accordance with the instructions for use (IFU). 
 
Post-procedure  care should be performed and prescribed in 
accordance with Investigator’s SoC  and as specified in the 
protocol.     
Data Collection  All data will be  collected via a n electronic data capture  (EDC ) 
system.  The Investigator and I nvestig ator’s staff will enter 
registry  data into the EDC through a web portal. Each 
Investigator and Investigator staff  member  is granted a unique 
login into the EDC platform.  
 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2.1 EMEA (19 -Oct-2018)   
     
  EKOS Corporation   CONFIDENTIAL  
  A BTG International group company   
3. SCHEDULE OF REGISTRY ASSESSMENTS – PROSPECTIVE  
Assessments will be  performed per Investigator’s SoC  and collected according to the schedule below. Ass essments marked with 
an asterisk (* ) pertain to an outcome measure or eligibility.  
 
Assessment   Baseline  Procedure/ Post Procedure  Follow -up  
Day -1 Day 0 thru Discharge  3 Months  
(±14 Days ) 
Post APT  
(Phone or Visit)  12 Months 
(±1 Month) 
Post APT  
(Phone or Visit)  
Informed Consent  X*    
Demographics  X*    
Medical history, risk factors  X*    
Vital signs1 X* X   
Physical Examination  X    
CTA X* X*3 (if collected)    
sPESI  X    
APT Procedure   X   
Echocardiogram2 X* X3 (if collected) X* (if collected)  X* (if collected)  
Quality of life surveys4  X* X* X* 
Laboratory tests5 X6 X   
Biomarkers7 X* X   
Adverse/VTE/Bleeding Events   X* X* X* 
Anticoagulation medications  X X X X 
1. Recor d heart rate, blood pressure, respiratory rate, oxygen  saturation vital signs at admission, at start and end of treatment, and 
once at same time each day of hospitalization  
2. Includes RV/LV ratio, TAPSE, estimated RVSP, and collapse of the inferior vena cava (IVC) with respiration  
3. Collect 24 – 48 hours after th e start of the APT procedure  
4. PEmb -QOL and EQ -5D-5L 
5. Hemog lobin (Hgb), hematocrit (Hct), p latelet count,  creatinine,  activated partial thromboplastin time ( aPTT ), partial thromboplastin 
time (PT), and international normalized ratio ( INR) 
6. Record if collected  within 48 hours prior to the start of APT procedure  
7. Troponin, brain natriuretic peptide ( BNP)/NT-proBNP, lactate/lactic acid, and D -dimer  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
4. BACKGROUND  
4.1 Pulmonary Embolism  (PE) 
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is the third most common cardiovascular disorder in the United States after 
myocardial infarction and stroke1. The 2008 United States Surgeon General’s Call to Action to 
Prevent DVT and PE estimates that 100,000 to 180,000 deaths occur annually from PE in the 
U.S. alone2. In the 2003 U.S. Healthcare Cos t and Utilization Project  Nationwide Inpatient 
Sample database, 196,134 VTE -related events, including symptomatic DVT, symptomatic PE, 
and VTE -related deaths, were calculated to have occurred among acutely ill hospitalized 
Medical Service subjects, afflicting two out of every 100 of these subjects3. 
The mortality rate for acute PE exceeds 15% in the first three months after diagnosis, 
surpassing that of myocardial infarction4. In nearly 25% of all subjects presenting with acute PE , 
the initial presentation is sudden death5. The majority of deaths from acute PE result s from right 
ventricular (RV) pressure overload and subsequent RV failure6. Survivors of acute PE are at -risk 
for developing debilitating chronic thromboembolic pulmonary hypertension  (CTEPH)7. Subjects 
with CTEPH typically experience a “honeymoon” period after acute PE, during which symptoms 
are absent despite the onset of pulmonary hypertension.  Unfortunately, the condition is usually 
detected wh en pulmonary hypertension has worsened to the point that it causes dyspnea, 
hypoxemia, and RV failure.  
Therapeutic anticoagulation with immediate parenteral anticoagulants followed by oral agents is 
the cornerstone of therapy for acute PE8. However, while  the majority of acute PE subjects has 
a benign clinical course with standard therapeutic anticoagulation alone, subjects with massive 
and submassive PE remain at increased risk for adverse clinical events, including RV failure 
and hemodynamic collapse.  
Advanced therapy for patients with acute PE is usually reserved for patients with either massive 
or submassive PE.  Options for advanced therapy include peripherally -administered systemic 
fibrinolysis, surgical pulmonary embolectomy, catheter -assisted embolec tomy, and inferior vena 
cava (IVC) filter insertion.  
Combined ultrasound/ fibrino lytic therapy was developed to accelerate thrombolysis and rapidly 
achieve complete clot lysis while reducing the risk of serious complications such as bleeding.   
High frequency, low power ultrasound accelerates thrombolysis both in vitro and in vivo.  This 
idea was pioneered by Kudo9 and confirmed by other investigators10,11,12. Ultrasound temporarily 
alters the local architecture of the fibrin clot, thereby enhancing i ts permeability by reducing the 
diameter of the fibrin strands and increasing the pore size of the fibrin mesh13. Ultrasound 
energy also provides an acoustic pressure gradient to enable transport of a greater quantity of 
thrombolytic drug into the clot its elf. The resulting faster, more complete clot lysis is due to 
increased diffusion of the thrombolytic agent into the clot and not mechanical disruption.   
EkoSonic® Endovascular System (EKOS) is an FDA cleared14 and CE Marked15 drug delivery 
catheter that u ses ultrasound delivered through the catheter core to speed the delivery of 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
physician -specified fluids, including thrombolytics,  into the interstices of the clot and increase 
the speed of lysis.  By making the clot more permeable and pushing the drug into t he fibrin 
mesh, EKOS has the potential to reduce time to lysis, effect more complete lysis, reduce drug 
dose and, thereby, reduce the risk of bleeding complications.   
EKOS Corporation investigated the effectiveness of thrombolytics delivered by ultrasound 
catheter in acute PE (symptoms ≤ 14 days) located in at least one main or proximal lobar 
pulmonary artery and with a RV/LV  of > 0.9 on chest CTA or echocardiogram in three 
prospective, multi -center studies that provide evidence for the efficacy and safety of the 
Acoustic Pulse Thrombolysis ( APT) procedure in the treatment of PE. There are published data 
for 370 subjects treated with the APT procedu re. The studies include one randomized -controlled 
study  ULTIMA  involving 30 of 59 patients  (pts); and two prospective studies: SEATTLE II 
involving 150 pts and OPTALYSE PE involving 100 pts.  
4.2 EkoSonic® Endovascular System (EKOS)  Product Description  
4.2.1  EKOS  Intended Use  
EKOS is intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in 
one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart 
dysfunction based on right heart pressures (mean pulmonary a rtery pressure ≥ 25 mmHg) or 
echocardiographic evaluatio n. 
4.2.2  EKOS  Description  
The EkoSonic® Endovascular System (EKOS) generates ultrasound waves in the treatment 
zone of the catheter through the piezoelectric conversion of radiofrequency energy. The 
ultraso und emanates radially from the treatment zone to improve the dispersion of infused 
physician -specified fluids, including thrombolytics.  
EKOS consists of two main components:  
1. Single -use sterile device, consisting of :   
a. Intelligent Drug Delivery Catheter (IDDC)  
b. MicroSonic Device (MSD)  
2. EkoSonic® Control Unit (reusable)  
The IDDC is 5.4 French with a 106 cm or 135 cm working length. It includes two luer ports for 
coolant and fluid delivery and an electrical connector for the thermocouples that monitor the 
catheter system temperature. Radiopaque markers are located approxim ately 1 cm proximal 
and 1 cm distal to the treatment zone. The IDDC central lumen is compatible with a 0.035” 
guidewire, accepts the MSD and delivers coolant during operation.  Fluid  and coolant flow 
through distal side holes for delivery in the treatment z one. Each  IDDC  requires its own  set of  
infusion tubing and infusion pump  for fluid and coolant.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
The MSD locks to the luer connector on the central lumen of the IDDC aligning the ultrasound -
generating segment to the treatment zone of the IDDC. The device uses multiple ultrasound 
transducers to emit ultrasound energy radially from the long axis of the catheter system.  
The EkoSonic® Control Unit provides electrical power to the piezoelectric elements in the 
treatment zone of the device and monitors operating  parameters during operation. The Control 
Unit also provides the user interface through the front panel display and keypad.  
4.2.3  EKOS  Regulatory Status  
In Europe, EKOS has an EC Design -Examination Certificate (CE  567229)  for the treatment of 
pulmonary embolism  with a ≥ 50% clot burden in one or both main pulmonary arteries or lobar 
pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures 
(mean pulmonary artery pressure ≥ 25 mmHg) . In this registry study , EKOS  is commercially -
available and being used in accordance with its cleared indications for use . Therefore, no 
special labeling or tracking is required for devices .  
4.3 EKOS  Clinical Summary  in Pulmonary Embolism  
ULTIMA,  SEATTLE II , and OPTALYSE PE  have shown various  APT regimen s using 
recombinant tissue plasminogen activator (r -tPA) for thrombolysis  to be safe and effective in the 
treatment of PE. Low dose r-tPA and reduction in treatment time of the APT procedure appear 
to reduce bleeding events and costs associated  with length of stay in the ICU and hospital.   
Pharmacology studies demonstrate that clot lysis occurs rapidly after r -tPA intravenous 
treatment and is ~90% complete by 90 minutes. A rabbit study demonstrated that thrombolytic 
activity after r -tPA, whethe r administered as an intravenous bolus dose or infusion is dose -
dependent and the duration of action is dose -independent16. After a single dose (0.5 to 0.4 
mg/kg), to 2.3 -3 kg rabbits, r -tPA was rapidly inhibited, resulting in duration of action of 15 
minu tes. The maximum extent of lysis after the bolus was 54% for a 0.4 mg/kg dose. During a 4 
hour infusion of r -tPA (0.625 to 1 mg/kg), 90% of the thrombolytic activity occurr ed within 2 
hours . The maximum extent of lysis after the infusion was 87% for a 0.5 mg/kg dose. After 
administration of either a bolus or infusion, continued lysis activity decreased exponentially with 
time and there remained an un dissolved  clot at the end of the measurement period  
Similarly, a pharmacodynamics study of r -tPA in man demon strated that even though the initial 
half-life of r -tPA in the systemic circulation is 3 -4 minutes, fibrinolysis after an intravenous 
infusion of 20 to 150 mg continues from 7 to 12 hours17. The prolonged duration of action 
demonstrates that plasmin bound to fibrin continues to be active after r -tPA is cleared from the 
circulation. As fibrin is lysed, r -tPA is released and is metabolized by the liver.  
The ability of r -tPA to lyse clot is dependent upon binding with fibrin and plasminogen in a 
centric terna ry complex to activate plasminogen to form plasmin which lyse fibrin into 
degradation products18. Clot lysis is diffusion dependent. By increasing permeation, lysis 
increases. Several in -vitro studies have demonstrated that ultrasound enhances both urokina se 
and r -tPA mediated lysis of plasmin and blood clots. Enhancement is seen at a range of 
frequencies, intensities and lytic concentrations19. This enhancement is seen in both static and 
flowing thrombolytic models. Animal studies report faster recanalizat ion times for clots exposed 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
to ultrasound during lytic treatment using r -tPA. These effects were seen at the frequencies 
produced by the EKOS catheter. The time of clot treatment in the studies was 30 minutes. From 
these studies, we postulate that r -tPA in  the presence of ultrasound will produce significant 
fibrinolysis within 2 hours of receptor binding and may continue for another 7 to 12 hours after 
the APT Procedure is complete. Thus, thrombus burden may be significantly reduced within a 
few hours of th e APT Procedure to restore pulmonary perfusion, reduce RV dilatation, and 
decrease pulmonary artery pressures.  
The earliest study of the APT procedure in PE demonstrated that doses of approximately 22 mg 
r-tPA delivered with the APT procedure over 25 hour s were effective in treating PE in subjects 
suffering from massive PE20. Since that time, doses used in treating PE have ranged from 0.5 to 
1 mg/hr/catheter delivered over an average of 18 hours, with no infusion duration being less 
than 12.9 hours (exclud ing one subject). Even though efficacy measurements have been made 
at 24 and 48 hours, clinicians have reported subjects often improve within a few hours of the 
start of treatment. These observations, along with the aforementioned pharmacology studies, 
provide evidence to support the scientific rationale for investigating the reduction in ultrasound - 
r-tPA treatment time.  
The OPTALYSE PE study was designed to investigate the lowest r -tPA dose -ultrasound 
treatment time required to achieve the same reductions in thrombus burden and associated 
improvement in physiologic parameters demonstrated in ULTIMA and SEATTLE II. Results  of 
the OPTALYSE PE study were intended to inform the study design for further studies of the 
APT procedure . Analysis of the first 100 evaluable subjects in the U.S. study  suggested 
equipoise between each study arm and therefore a sample size was extended to additional sites 
in the U.K.  Improvement in the RV/LV diameters  by core laboratory -assessed 
echocardiographic  reads  were  -0.17, -0.17, -0.12, and -0.29 at 4 hours and -0.22, -0.25, -0.18, 
and -0.32 at 48 hours in patients randomized to 8 mg/2 hrs, 8 mg/4 hrs, 12 mg/6 hrs, and 24 
mg/6 hrs, respectively .21 Improvement in modified Miller score wa s also seen in all groups22.  
5. REGISTRY OBJECTIVE AND PURPOSE  
5.1 Objectives  
The obj ectives of this registry are:  
• To understand the APT treatment protocol used as SoC across institutions and 
document changes in practice following the OPTALYSE PE study results  
• To descri be the effects of varied APT  protocols on long -term patient outcomes  
5.2 Design  
This multicenter, international registry is designed to retrospectively and prospectively collect 
treatment and outcome data related to pts with submassive  (Intermediate -High Risk)  or massive  
(High Risk)  PE undergoing the APT treatment. Subjects are treated per Investigator’s SoC and 
in accordance with the IFU.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Intermediate -High Risk PE will be defined by evidence of RV dysfunction (RV/LV > 1.0), 
hemodynamic stability (normal systemic arterial blood pressure >90 mmHg), and Troponin 
elevation . 
High Risk PE will be defined by hemodynamic instability (normal systemic arterial blood 
pressure <90 mm Hg and/or use of vasopressors).23 
Retrospective case data will consist of treatment and health outcomes of consecutive patients 
treated  with APT between  Janu ary 1, 2014  and one year prior to date of site activation . 
Prospective subject data will consist of treatment and health outcomes of treated subjects since 
the site was activated to participate in the registry. For each treated subject enrolled, 
participat ion in the registry lasts approximately 12 months.  Subjects  should be followed per 
Investigator’s SoC . Data will be collected for any echocardiograms and CT As completed. At 
minimum, a health status check should be performed at 3 and 12 months. For patients  with an 
abnormal echocardiogram post -APT treatment, a n on-site visit with echocardiogram should be 
performed at  3 months to assess for chronic pulmonary hypertension. An echocardiogram at 12 
months is also requested  for all patients . Safety data should be  reported through 12 months 
post-index procedure.  
5.3 Outcome Measures  
1. Change in the ratio of the m easurement of the RV/LV diameters as measured by 
echocardiogram or CT A from baseline to  between 24 – 48 hours after the start of the APT 
procedure  (matched pairs as available) . 
2. Diagnosis of pulmonary hypertension defined  as mean  pulmonary artery pressure greater 
than 25 mm  Hg by echocardiogram  that persists at least 3 months after PE diagnosis   
3. Frequency and  safety  outcomes of adjunctive therapies post APT procedure during 
hospitalization  
4. Number of patients with non or partial response to other interventional procedures prior to 
APT procedure for index PE  
5. Frequency and severity of SAEs  related to EKOS  and procedure, major bleeding, or VTE 
during index hospitalization  and during  first 12 months  post-APT procedure  
6. All-cause mortality during first 12 months post-APT procedure  
7. Recurrent symptomatic PE, PE related death, hemodynamic collapse  at 30 days (com posite 
measure)  
8. Healthcare utilization during hospitalization:  
a. Time from hospital admission to ICU  discharge  
b. Time from hospital admission to discharge  
9. Quality of li fe (QOL) as measured by the PEmb -QOL  and EQ-5D-5L at  baseline and  3 
month and 12 month  post-hospitalization subject follow -up visits  
10. IVC filter placement (measured by number of occurrences)  
6. SUBJECT SELECTION  
6.1 Registry Population  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
This registry is designed to collect data related to APT treatment in patients experiencing 
symptoms of submassive or massive PE with a baseline RV/LV > 1.0.Data will be collected for 
up to  1000 retrospective cases and 550 prospective subjects selected by their physician to 
receive APT treatment for PE. E nrollment will occur at up to 100  investigational sites globally.  
6.2 Subject Selection  
6.2.1  Inclusion Criteria  
Retrospective cases must meet all of the following inclusion criteria:  
1. Treated with APT procedure between  January  1, 2014 and one year prior to date of site 
activation  
2. RV/LV > 1.0 from diagnostic CTA or echocardiogram  
3. PE symptom duration < 14 days  
4. Troponin elevation  
Prospective subjects must meet all of the following inclusio n criteria:  
5. Male or female > 18 years of age and < 80 years of age  
6. RV/LV > 1.0 from diagnostic CTA  or echocardiogram  
7. PE symptom duration < 14 days  
8. Troponin elevation  
9. Signed informed consent obtained from subject or legally authorized representative  
10. Investigator has selected  EKOS  to treat patient with massive or submassive PE  
6.2.2  Exclusion Criteria  
Retrospective cases must not meet the following exclusion criteria:  
11. Enrollment into the OPTALYSE PE study  
Prospective subjects must not meet any  of the following exclusion criteria:  
12. Clinician deems the subject high -risk for catastrophic bleeding  
13. Life expectancy < one year  
6.3 Subject Completion  
A subject will be considered to have successfully finished the registry upon c ompletion of their 
12 month fo llow-up.  
6.4 Withdrawal  
For cases in which the subject does not complete all assessments and follow -up visits, the 
subjects will be classified as follows:  
• Investigator withdrawal – Investigator can withdraw a subject from the registry for a 
safety concern  or non-compliance. Reason for Investigator withdrawal of a subject and 
last date of contact for the registry will be documented in the EDC  system .  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
• Subject withdrawal – Subjects may withdraw from participation at any time during the 
registry. All d ata collected prior to withdrawal shall remain part of the registry data. 
Reasonable effort should be made to encourage the subject to remain in the registry. If 
the subject declines further participation, the reason for withdrawal will be documented in 
the EDC  system .  
• Lost to follow -up – The site should collect three methods to contact a subject. A subject 
will be considered lost to follow -up if there are at least three documented attempts to 
contac t the subject for the ir last expected follow -up without s uccess. Last date of contact 
will be documented in the EDC  system . 
7. CASE DATA COLLECTION – RETROSPECTIVE  
7.1 Protected Health Information (PHI) Authorization   Waiver  
The sites  participating in retrospective case data collection  will apply for a PHI authorizatio n 
waiver with the relevant IRB/EC to review, use, and submit specific case data to the Sponsor. 
The specific case data is outlined in the Measurements -Retrospective section of the Protocol 
and will be de -identified  before being entered into the EDC system.  
8. MEASUREMENTS – RETROSPECTIVE  
8.1 Screening /Baseline  
The following data will be collected for screening , as available . Record most recent 
assessments prior to beginning of APT procedure . 
• Review and confirmation of eligibility to participate in the regis try 
• Demographic information, medical history, and clinical risk factors  
• CTA to evaluate the anatomic location of PE and degree of RV enlargement (as part of the 
initial diagnosis of PE). The RV/LV ratio at end -diastole will be determined from this image.  
• Echocardiogram to measure: RV/LV ratio, TAPSE, estimated RVSP, and the collapse of the 
IVC with respiration  
• Laboratory tests   
o Hemoglobin (Hgb)  
o Hematocrit (Hct)  
o Platelet count  
o Bleeding Times: aPTT, PT, and INR  
o Biomarker measurements: Troponin  (to confirm eligibility) , BNP/NT -proBNP, 
lactate/lactic acid, and D -dimer  
• Anticoagulation medications  72 hours  leading up to  the APT procedure  
8.2 Procedure  
The following data will be collected:  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
• Vital signs prior to initiation of procedure  
• APT procedure treat ment details  
8.3 Post-Procedure  
The following data will be collected as available:  
• First set of v ital signs after end of  APT procedure  
• Laboratory tests  
o Hemoglobin (Hgb)  
o Hematocrit (Hct)  
o Platelet count  
o Creatinine  
o Bleeding Times: aPTT, PT, and INR  
o Biomarker measurements: Troponin, BNP/NT -proBNP, lactate/lactic acid, and D -
dimer  
• Echocardiogram 24  – 48 hours after start of APT  procedure: RV/LV ratio, TAPSE, estimated 
RVSP, and the collapse of the IVC with respiration  
• CTA 24 – 48 hours after start of APT procedure: RV/LV ratio  
• Vital signs once at same time each day of hospitalization through discharge  
• Length of post -procedure hospitalization (date and time of hospital discharge)  
• SAEs  related to EKOS  or procedure , bleedi ng events, or VTE events  
8.4 Long Term Health Data  
The following data will be collected as follow up data,  up to 12 months  post index APT 
procedure , as available:  
• Occurrence of VTE or bleeding events ,  
• Changes in anticoagulation medications  
• Echocardiogram s: RV/LV ratio, T APSE, estimated RVSP, and the collapse of the IVC with 
respiration  
• Mortality, including cause  
9. TREATMENT OF SUBJECTS - PROSPECTIVE  
9.1 EkoSonic® Endovascular System (EKOS)  
9.1.1  APT Procedure  
The APT procedure must be performed by an experienced interventional cardio logist, vascular, 
cardiac  or cardiothoracic surgeon, or radiologist in an angiographic suite with digital 
angiographic equipment.  Proper placement of EKOS to treat PE will be performed using 
standard image guidance techniques associated with catheterizatio n of the pulmonary artery.  
Choice of venous access is at the discretion of the treating physician and in alignment with the 
hospital standard of care22. 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Infusion of physician -specified fluids will be  at the physician -prescribed dose . Infusion  of fluid  
and s aline coolant will be started. The MicroSonic Device will then be activated  at start of 
infusion . If technical difficulties are encountered which interfere with proper operation of the 
system or infusion, the Instructions for Use will be consulted to assist in resolution of the issue. 
If the issues cannot be resolved, the affected device will be exch anged for another EKOS  
device. This exchange and serial numbers  will be recorded in the EDC system. The affected 
device will be saved and returned to the Sponsor.  
9.1.2  Post-treatment Management  
Following treatment with EKOS, subjects should be treated with the Investigator’s SoC. 
Anticoagulation medication should be prescribed according to physician’s clinical judgement.  
9.1.3  Duration of Treatment and Follow -up 
Following the initial treatment with EKOS, each subject is followed  per their Investigator’s SoC 
follow up  schedule . At minimum, a 3 and 12  month  post-APT procedure phone call or visit 
should be made to record  health status . During the follow -up period, subjects are followed for 
re-hospitalizations, recurrence of VTE, and  other clinical outcomes . Any echocardiograms 
collected during follow -up should be recorded in the EDC system. The final health status of the 
subject  will be reported  in the EDC system.  A final echocardiogram at 12 months is requested.  
9.1.4  Adjunctive Interven tions  
Investigator may utilize any adjunctive interventions as deemed necessary according to their 
clinical judgement. Investigator will note any adjunctive interventions to the APT procedure  for 
the treatment of PE  including type, start date, and stop da te in the EDC system.  
10. MEASUREMENTS AND EVALUATIONS - PRO SPECTIVE  
10.1 Screening /Baseline  (Day -1) 
The screening phase begins when the ICF is fully signed and dated and ends at the initiation of 
the APT procedure.   
The following should be completed prior to data being collected about the patient:  
• Review and signing of the ICF  
• Review and confirmation of eligibility to participate in the registry  
The following evaluations should be  recorded if performed  as part of routine clinical care at 
Screening/ Baseline  (within 48 hours of the initiation of treatment) : 
• Physical examination and collection of demographic , medical history, and clinical risk factors 
information  
• sPESI  
• CTA to evaluate the anatomic location of PE and degree of RV enlargement (as part of the 
initial diagnosis of PE). The RV/LV ratio at end -diastole will be determined from this image.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
• Echocardio gram to measure: RV/LV ratio, TAPSE, estimated RVSP, and the collapse of the 
IVC with respiration  
• Laboratory tests  
o Hemoglobin (Hgb), Hematocrit (Hct)  
o Platelet count  
o Creatinine  
o Bleeding Times: aPTT, PT, and INR  
o Biomarker measurements: Troponin  (required for inclusion) , BNP/NT -proBNP, 
lactate/lactic acid, and D -dimer . 
• Anticoagulation medications leading up to  the APT procedure  
10.2 Procedure Visit (Day 0) 
The following data should be  recorded  from the procedure : 
• Vital signs immediately prior to the procedure  
• APT procedure  details   
Select sites may also perform an integrated bedside assessment as described in Section 
11.1.8.  
10.3 Post Procedure Assessments  
The following should be recorded if performed after the APT pro cedure is completed:  
• Vital signs immediately after the procedure  
• Laboratory test  result s from clinical routine will be collected  at 24  (± 3) hours  post-start of 
APT procedure : 
o Hemoglobin (Hgb)  
o Hematocrit (Hct)  
o Platelet count  
o Creatinine  
o Bleeding Times: aPTT, PT, and INR  
o Biomarker measurements: Troponin, BNP/NT -proBNP, lactate/lactic acid, and D -
dimer  
• Echocardiogram 24 – 48 hours after the start of the APT procedure to measure: RV/LV 
ratio, TAPSE, estimated RVSP, and the collapse of the IVC with r espiration  
• CTA 24 – 48 hours after start of APT procedure: RV/LV ratio  
• Vital signs once at the same time each day of hospitalization until discharge.  
• Quality of Life surveys: PEmb -QOL and EQ -5D-5L 
• Change in anticoagulation medications until discharge.  
10.4 Follow -Up 
Patients will be followed per Investigator’s SoC for up to 12 months  post-APT procedure.  At 3 
months and 12 months post -APT procedure, the following data should be recorded, as 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
available. For patients with an abnormal post -treatment ec hocardiogram, a 3 -month follow -up 
echocardiogram is recommended to assess for chronic pulmonary hypertension. For other 
patients, 3 -month data can be collected via phone or on -site visit.  
• Echocardiogram: RV/LV ratio, TAPSE, estimated RVSP, and the collapse  of the IVC with 
respiration  
• Review any SAEs, hospitalizations. Record any SAEs related to occurrence of VTE or 
bleeding events  
• Review any changes in anticoagulation medications  
• Quality of  Life surveys: PEmb -QOL and EQ -5D-5L 
• In case of mortality, review ca use and time of occurrence  
• In case of withdrawal, review cause and time of occurrence  
If additional echocardiogram(s) are collected outside of the 3 and 12 month follow -up, the 
results should be recorded in the EDC.  
11. Evaluations  
11.1 Informed Consent  Process  
Patients with the potential to meet eligibility criteria for the prospective arm will be offered the 
opportunity to be evaluated for participation in this registry. All such patients must sign an ICF 
approved by the relevant IRB/EC before any tria l-related evaluations can be performed.  
Investigator or qualified delegate will review the registry consent form  with the patient and the 
patient must have an opportunity to ask questions about what data will be collected, the follow -
up schedule, and what options the patient has if they do not participate in the registry prior to 
signature. The patient will receive a copy of the signed ICF to keep for their records.  
Subjects will be informed of any revisions of the ICF and relevant revisions will be signed and 
kept in the subject’s file.  
The consenting process, acquisition of the ICF and any revisions should be documented in the 
subject’s medical record and the ICF s hould be signed and dated by the individual who 
conducted the informed consent discussion.  
11.2 Eligibility Review  
A patient is to review and sign an ICF prior to any evaluations to assess eligibility in the registry. 
Subjects who are found to meet all inclusio n criteria and no exclusion criteria will be entered into 
the EDC system.  
11.3 Assignment of Subject Identification Number  
All retrospective cases and prospective s ubjects who meet eligibility criteria for the registry are 
assigned a subject identification (ID ) number by the EDC system. The subject ID number is 
used to de -identify subject data of protected health information in the EDC. Investigator will 
maintain a subject ID list of subjects’ names and associated IDs which allows Investigator to 
determine iden tity of all subjects.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
11.4 Demographics  
For each subject, year of birth, and gender  are collected. In some countries,  race and ethnicity 
are collected.  
11.5 Physical Examination  
All prospective patients will undergo a physical examination at screening, in accordanc e with the 
Investigator’s current practice, to include height and weight.  Available data will be collected for 
retrospective cases.  
11.6 Vital Signs  
Vital signs including systolic/diastolic blood pressure, heart rate, respiratory rate, and SpO 2 will 
be collecte d. Vital signs will be collected at baseline , prior to and immediately after the APT 
procedure, and once per day of post -procedure hospitalization until discharge.  
11.7 Anticoagulation and Concomitant Medications  
History of anticoagulant medication up to three days prior to the start of the APT procedure will 
be obtained. Changes in anticoagulation medications after discharge will be recorded in the 
EDC system throughout the 12 -month follow -up period.  
Other concomitant (non -anticoagulation) medi cations will be r ecorded in the EDC system 
through 12 mont h follow -up only for medications prescribed to trea t SAE s related to the 
procedure or device , bleeding  events , or VTE event s. 
11.8 Quality of Life Assessments: PEmb -QoL and EQ -5D-5L 
Two Q uality of Life  instru ments , PEmb -QOL and EQ -5D-5L, will be used in this registry  and are  
validated, widely used quality of life assessments.   
The PEmb -QOL quantifies health -related quality of life after experiencing PE. This questionnaire 
consists of 10 questions for six health dimen sions: frequency of complaints, activities of daily 
living limitation, work -related problems, social limitations, intensity of complaints, and emotional 
complaints.  
The EQ -5D-5L is a patient reported outcome that provides a simple descriptive profile and 
single index value for health status. The questionnaire consists of 5 questions pertaining  to 
specific health dimensions,  including mobility, self -care, usual activities, pain/discomfort, 
anxiety/depression, and overall health status rating scale.  
Subjects ’ responses to the questionnaire s are to be recorded and entered into the EDC system.  
11.9 Integrated Bedside Assessment   
At select participating sites : In addition to the vital signs specified in Section 10, bedside vital 
signs including systolic/diastolic blood pressure, heart rate, respiratory rate, capillary refill time 
and SpO 2 will be recorded at 30 minute interval s from the start of the APT procedure  through  
four hours after the end of the APT procedure.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Along with the echocardiogram s specified in Section 10, additional limited echocardiograms will 
be performed at the bedside for RV/LV ratio measurements hourly after the start of the APT 
procedure through four hours after the end of the APT procedure.  
The purpose for the collection of  vital signs every 30 minutes and focused echocardiography 
every hour is to correlate change in clinical parameters (vital signs) with change in markers of 
RV strain (RV/LV ratio) documented using  echocardiography as a non-invasive imaging 
method. There is  preliminary evidence from the first 100 patients in OPTALYSE PE that the 
right heart recovers within a couple hours of treatment. Confirmation for this finding will be 
important in identifying the best APT protocol . The echocardiogram is the most sensitiv e non -
invasive, real -time method outside of a CT scan to image both ventricles of the heart and 
quantify RV strain. The collection of routine bedside vital signs and limited echocardiograms 
(RV/LV ratio only) do es not increase the potential risk to the pts  participating in the registry as 
they are non -invasive measurements that will be collected at the bedside from a limited number 
of sites during the conduct of the registry.   
12. SAFETY REPORTING  
12.1 Definitions  
12.1.1  Adverse Event  
An adverse event (AE) is any untowar d medical occurrence observed in a subject that develops 
or worsens from the time of enrollment, whether or not considered intervention -related. An AE 
can be any unfavorable or unintended sign, symptom, or disease temporally associated with the 
use of an i ntervention and does not imply a judgement about causality.  
12.1.2  Serious Adverse Event (SAE)  
A SAE  is any untoward medical occurrence resulting in any of the following outcomes:  
1. Death  
2. Life-threatening (Note: The term “life -threatening” refers to an event in wh ich the subject 
was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe)  
3. Inpatient hospitalization or prolongation of existing hospitalization  
4. Persistent or significan t disability/incapacity  
5. Congenital abnormally or birth defect  
6. Important medical event that may not result in death, be life -threatening, or require 
hospitalization but may jeopardize the subject and may require medical or surgical 
intervention to prevent o ne of the outcomes listed in this definition.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
12.1.3  Unexpected Adverse Event  
An AE is considered unexpected if it is not listed in the IFU, package insert, or not listed at the 
specificity or severity that has been observed.  
12.1.4  Pre-Existing Medical Condition  
Pre-existing medical conditions are those that are present at enrollment . If the frequency, 
severity, or character of the condition worsens significantly or unexpectedly during the registry , 
the condition will be an AE . 
12.1.5  Device Failures and Malfun ctions  
A device failure is defined as the device being used in accordance with the IFU, but does not 
perform according to the IFU and negatively impacts the treatment.  
A device malfunction is defined as an unexpected change to the device that is contradict ory to 
the IFU and may or may not affect device performance.  
12.1.6  Major Bleeding  
The following definition24 of major bleeding will be used:  As general principles, a definition of 
major bleeding will be based on objective criteria, and major bleeds are those that result in 
death, are life -threatening, cause chronic sequelae or consume major health -care resources. 
With this in mind, the Control  of Anticoagulation Subcommittee recommends the following 
criteria for major bleeding in non -surgical subjects:  
1. Fatal bleeding, and/or  
2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, 
retroperitoneal, intra -articular or pericardial, or intramuscular with compartment syndrome, 
and/or  
3. Bleeding causing a fall in hemoglobin level of 20 gL-1 (1.24 mmol L-1) or more, or leading to 
transfusion of two or more units of whole blood or red cells.  
Note: For this protocol , a fall in Hgb of 20 gL-1 (1.24 mmol L-1) or more with no objective 
evidence of bleeding or symptoms of bleeding will not be considered a major bleeding event.  
12.2 Reporting Requirements  
Investigators are not required to report all AEs that occur in the regis try. 
Investigators  must report  the following SAEs  to Sponsor within one working  day of becoming 
aware of the event for either retrospective or prospective patients. SAEs should be reported up 
to each subject’s 12-month  follow -up:  
• those related to EKOS  or APT procedure  
• those related to a bleed  
• VTE events  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
The type of event, severity, and relationship to EKOS , procedure,  thrombol ytic, and 
anticoagulatio n drug will be reported by the I nvestigator.  
Device failures and malfunctions will be reported in the EDC system within one working day 
after Investigator or delegate learn s of the event . For prospective patients, these will also be 
reported to the relevant IRB/EC as required per IRB/EC requirements . 
Because EKOS is a commercial ly-available  medical device, Investigators will comply with any 
hospital user reporting requirements.  
If additional safety information becomes available during the course of the registry, Sponsor will 
amend the protocol and IC F as necessary.  
13. STATISTICAL CONSIDERATIONS  
13.1 Statistical Analysis  
The statistical analysis plan (SAP) will be a separate document finalized prior to data analysis. 
The SAP  will be updated as required, in association with any protocol amendments. The plan 
will include detailed descriptions of analysis methods, tables, listings and figures and will 
describe statistical programming considerations.  
For descriptive statistics, continuous data (e.g., age) will be summarized with n, mean, median, 
standard deviation,  minimum and maximum and categorical data (e.g., gender) will be 
summarized with observed counts and percentages for each category.  
Patients will be analyzed according to the APT treatment protocol they received ( i.e. duration of 
treatment and dose, type o f fluid received ). Frequency of use of each of the APT treatment 
protocols before and after OPTALYSE PE results were made public will be summarized and 
compared using fisher’s exact test.  
Each outcome measure will be summarized for the full registry popul ation as well as separately 
by the different APT treatment protocols , including 95% c onfidence intervals. Additionally, 
outcome measure s will be summarized by the following subgroups: submassive and massive 
PE, each  region,  and by the  retrospective  and prospective  portion s of the registry .  
13.2 Determination of Sample Size  
For retrospective cases, up to 1000 cases will be collected to capture details of PE treatment 
with EKOS from the time it became commercially available to the time the s ite was activated. 
For prospective, up to 500 patients will be treated to collect data on current EKOS use at up to 
100 sites.     
13.3 Analysis Populations  
The SP will be defined as all patients who receive the APT procedure. Safety and effectiveness 
summaries  will be reported for the SP. 
The EP will be defined as all patients who meet eligibility criteria . An additional effectiveness 
summary will be reported for the EP. 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
13.4 Patient Disposition  
The number of patients with the study completion status and the reasons  for discontinuation will 
be summarized.  
13.5 Baseline and Demographics Characteristics  
Descriptive statistics  will be used to summarize demographics and baseline characteristics  
including pertinent PE history.  
13.6 Measurement of APT treatment  
APT treatment and procedure details will be summarized.  Patients will be analyzed according to 
the APT treatment protocol they received (e.g., >6h/>24mg; 6h/12 -24mg; 6h/6 -12mg; 4h/4 -8mg; 
2h/4-8mg, other). Frequency of use of each of the APT treatment protocols  before and after 
OPTALYSE PE results were made public will be summarized and compared using fisher’s exact 
test.  
13.7 Efficacy Outcome Measures  Analyses  
Descriptive statistics  will be used to summarize efficacy outcome measures  RV/LV, TAPSE, IVC 
Collapse, es timated RVSP and pulmonary arterial pressure by time point and /or study visit 
including change from baseline for continuous endpoints.  
Each efficacy outcome measure will be summarized for the full registry population as well as 
separately by the different APT treatment protocols, including 95% confidence intervals. 
Additionally, efficacy outcome measure s will be summarized by the following subgroups: 
submassive and massive PE,  each  region,  and by the  retrospective  and prospective  portions of 
the registry . 
13.8 Additional Outcome  Analyses  
Descriptive statistics will be used to summarize additional outcome assessments including:  
• Healthcare utilization during hospitalization will be summarized for time from hospital 
admission to ICU and time from hospital admission  to discharge.  
• Quality of life (QOL) measures PEmb -QOL and EQ -5D-5L will be summarized by time point 
and /or study visit including change from baseline for continuous endpoints and shift tables 
for categorical endpoints.  
• Frequency and outcomes  of adjunctive therapies post APT procedure during hospitalization  
• Number of patients with non or partial response to other interventional procedures prior to 
APT procedure for index PE  
• IVC filter placement (measured by number of occurrences)  
13.9 Safety Analyses  
Safety analyses will be conducted on the SP  during hospitalization and through the 12-month 
follow -up period. AEs and SAEs will be summarized by MedDRA System Organ Class and 
Preferred Term.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
In addition, occurrence of safety outcomes will be summarized , including diagnosis of 
pulmonary hypertension, all-cause mortality during first 12 months, composite measure of 
recurrent symptomatic PE, PE related death or hemodynamic collapse at 30 days .  
13.10  Interim Analysis  
Periodic statistical summaries will be prepared annually.  
13.11   Handling of Missing Data  
All observed data will be summarized without imputation for missing values.  
14. DATA MANAGEMENT  
All data management (DM) processes up to and including post database lock will be detailed in 
the Data Management Plan  (DMP) , including the processes for import of external data (e.g. 
Laboratory Data), coding and SAE reconciliation. . 
Data from the study will be collected via EDC. Clinical data will be extracted in the required 
format by BTG DM from the Datatrak EDC database on an ongoing basis.  
Data must be accurately transcribed into the eCRF (ideally within 48 hours after the visit has 
occurred for the patient) by the study site and must be verifiable from source data. Examples of 
source documents are hospital reco rds which include the patient’s medical notes, laboratory 
and other clinical reports etc.  
Where copies supporting s ource documentation (e.g. CT  scan images etc.) are being submitted 
for the study, the patients’ study number must be clearly indicated on all  material and any 
patient identifiers removed/redacted prior to sending to maintain confidentiality.  
Training will be provided in the form of eTrain to all users accessing the EDC system from 
Datatrak. Details of the requirement will be outlined in the DMP . 
15. LEGAL/ETHICS AND  ADMINISTRATIVE PROCEDURES  
15.1 Good Clinical Practice/Regulatory Compliance  
The procedures set out in  this protocol , pertaining to the conduct, evaluation, and 
documentation of this registry , are designed to ensure that Sponsor  and Investigat ors abide by 
the Declaration of Helsinki, International Con ference on Harmonisation Guideline E6 (R2 ): Good 
Clinical Practice  (GCP) . 
It is Investigator’s responsibility to ensure that adequate time and appropriate resources are 
available at the investigational  site prior to commitment to participate in this registry . Investigator 
should also be able to estimate or demonstrate the potential for  recruiting the required number 
of suitable subjects within the agreed recruitment period. Investigator maintain s a list of 
appropriately qualified person s to whom Investigator has delegated significant registry -related 
tasks.  
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
15.2 Site and Investigator Qualifi cation  
All participating investigational sites are assessed  by Sponsor to verify that they are able to 
conduct the registry . Each participating institution must have an established IRB /EC and clinical 
protocol review process that is compliant with  the rele vant government regulation , ensuring the 
clinical protocol can be adequately evaluated and approved at the institutional level.  
The Institution must have appropriately qualified investigators  and clinical and administrative 
support staff in place to adequa tely conduct the registry  according to  the principles of  
International Con ference on Harmonisation  GCP in general and must have the adequate 
expertise and staff to conduct this registry  in compliance with the relevant guidelines and 
regulations and to treat PE with EKOS.  
This registry  is scheduled to be performed by qualified, experienced investigators at up to 100 
research facilities in the United States , Europe , and Asia . Given that th e registry  is intended to 
collect data related to SoC treatment with EKOS , special care will be taken to select 
investigators with  experience in the treatment of  PE with EKOS.   
Site and Investigator qualification is primarily accomplished through a Site Qu alification Form 
and a qualification phone interview. In some cases, a  remote or on-site qualification visit may be 
performed.  
15.2.1  Investigator C urriculum Vitae (C V) 
Investigator and all investigational site staff will provide Sp onsor with his/her  current  (signed and 
dated within 2 years upon site activation)  CV and any revisions/updates.   
15.2.2  Statement of Investigator  
Investigator must sign and date the Statement of Investigator /Protocol Signature Page of this 
protocol for the original and each subseq uent amendment of the protocol and return a signed 
copy to Sponsor.  
15.3 IRB/EC Protocol Approval  
It is the responsibility of Investigator  or de legate  to submit this protocol , the ICF (approved by 
Sponsor), relevant supporting information and all types of subject recruitment information to the 
IRB/EC for review and approval prior to investigational site initiation. A copy of the written 
approval of the protocol and ICF  and/or protected health information authorization waiver  must 
be received by Sponsor prio r to the collection of patient case data or recruitment of subjects.  
Investigator or delegate is responsible for keeping the IRB /EC apprised of the progress of the 
registry , any changes to the protocol , deviations from the protocol and reportable adverse 
events . 
15.4 Informed Consent – Ethical Compliance  
For participation in the prospective portion of the protocol, Investigator or delegate provides 
Sponsor with a copy of the IRB /EC-approved consent form and a copy of the IRB /EC written 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
approval, prior to invest igational site initiation. Additionally, if the IRB /EC requires modifications 
to the ICF, the documentation supporting this requirement must be provided to Sponsor.  
It is the responsibility of Investigator  or delegate  to obtain written informed consent  from 
subjects prior to enrolling them into the prospective part of the study . All consent documentation 
must be in accordance with applicable regulations and  the principles of International Con ference 
on Harmonisation  GCP  Guidelines . Each subject or the subject’s legally authorized 
representative (where applicable) is requested to sign the  ICF after the subject has received 
and read written information and received an explanation of the registry , including but not limited 
to: the obj ectives, treatment plan, potential benefits and risk, inconveniences, alternative 
treatment options and the subject’s rights and responsibilities. A copy of the ICF must be given 
to the subject or the subject’s legally authorized representative  (where appl icable) . If applicable, 
it is provided in a certified translation of the subject’s local language.  
Acquisition of the informed consent should be documented in the subject medical record and 
the ICF should be signed and dated by the subject and the individual who conducted the 
informed consent discussion. Signed consent forms must remain in each subject’ s registry  file 
and must be available for review by the clinical research associate ( CRA ) or auditor  at any time.  
15.5 Subject Privacy and Confidentiality  
Sponsor and Investigator affirm and uphold the principle for the subject’s right to protection 
against in vasion of privacy. Throughout this registry , all data collected and analyzed by Sponsor  
is treated confidentially and identified by a  subject ID number.   
To verify compliance,  Sponsor may re quire access to the subject’s primary medical record to 
review those portions that directly concern this registry  (including but not limited to radiology 
images and hospital and outpatient records).  
As part of required content of the ICF, the patient must  be informed that his/her records may be 
reviewed by Sponsor, S ponsor representative and/or a representative of the appropriate 
regulatory agency . The ICF or related document must also state that patient privacy will be 
maintained pursuant to local regulat ions. Should access to such medical records require a 
waiver or authorization separate from the statement of informed consent, Investigator obtain s 
such permission in writing from the subject before the subject is entered in the registry . 
Data collected du ring this registry  may be used to support the development  or marketing of 
EKOS. Collected data may be reviewed by Sponsor and/or its representatives, independent 
auditors who validate the data on behalf of Sponsor, national or local regulatory authorities and 
the IRB /EC which granted approval for this registry  to proceed.  
15.6 Monitoring  
Monitoring the subject data is performed  using three methods: centralized, remote and on -site. 
All monitoring activities are performed by qualified personnel from S ponsor. Inves tigator and 
his/her staff are expected to cooperate with the  Sponsor  and be available during the visit to 
answer questions and resolve action items.   
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
Monitoring activities are documented through various means, which include monitoring visit 
reports and documentation of centralized monitoring activities. For on -site visits, t he CRA  
record s the date , a summary of the status and progress of the registry , and proposed actions.  
15.7 Modification of the Protocol  
All amendments to th is protocol must be documented in writing, reviewed and approved by 
Investigator , Sponsor , and  IRB/EC prior to implementation . If the protocol amendment 
substantially alters the design o r potential risk to the subject, new written informed consent must 
be obtained from each subject for continued partici pation in the registry . 
15.8 Suspension or Termination of Registry  
If conditions arise requiring further clarification before the decision can be reached to proceed 
with or terminate the registry , the registry  will be suspended until the situation has been 
resolved.  
Sponsor has the right to terminate this registry  at any time. Examples of situations where this 
might occur include:  
• It becomes app arent that enrollment is unsatisfactory with respect to quality and/or 
quantity or data recording is chronically inaccurate and/or incomplete.  
• The incidence and/or severity of adverse events in the registry  indicate a potential health 
hazard caused by the treatment.  
15.9 Protocol Deviations /Violations  
Protocol deviations /violations not related to the informed  consent process or eligibility are not 
required to be reported to Sponsor for this registry . Every attempt should be made to perform 
procedures and collect data according to this protocol . Protocol deviations/violations related to 
informed consent or elig ibility should be reported to the IRB /EC, per IRB /EC reporting 
requirements. Copies of these reports and IRB /EC notification of receipt of these reports shall 
be submitted to Sponsor.  
15.10  Recording, Access to and Retention of Source Data  
Investigators are re quired to prepare and maintain adequate source documentation which 
includes:  
• Documents that verify eligibility criteria  
• Records covering subject participation in the registry  including basic identification 
information, results of physical examinations and diagnostic tests, treatment 
administration, and visit/consult notes  
All key data must be recorded in the subject’s source documents including the informed consent 
acquisition.  
The CRA , auditors, IRB /EC, or regulatory inspectors may check data entered  again st the source 
documents. The consent form must include a statement by which the subjects allow the above -
named access to source data that substantiate  data entered  in the EDC system . These 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
personnel, bound by privacy laws and professional secrecy, will not disclose any personal 
information or personal medical information.  
As described in the International Con ference on Harmonisation  GCP Guidelines, ‘essential 
documents’, including final data set , source documents , IRB/EC appro vals, and consent forms 
should be retained by Investigator until at least two years have elapsed since the formal 
discontinuation of the registry . These documents should be retained for a longer period however 
if required by the applicable regulatory requi remen ts or by an agreement with S ponsor. 
Investigator must obtain written permission from Sponsor prior to destruction of any registry  
document.  
15.11  Final Data  
Investigator is responsible for maintaining adequate and accurate source documents from which 
accurate information is transcribed into the EDC system , which is designed to capture all 
pertinent data for the registry . Data entry s hould be completed by Invest igator or delegate , as 
delegated on the Delegation of Authority Log.  
Once the data ha ve been reviewed by the CRA , queries may be raised  in the EDC system  if the 
data are missing, unclear or contradictory. Once all data is entered and all queries resolved , 
Investigator will sign the completed data electronically  via the Investigator Signature section of 
the EDC system  and the database will be  locked. The final data set will be  provided to the site 
by Sponsor for archiving.  
15.12  Publications  
No individu al Investigator may publish results from his/her investigational  site until after 
publication of the primary manuscript describing the full population.  
The detailed obligations regarding the publication of any data, material results or other 
information th at is generated or created in relation to the registry  is set out in the Clinical Trial 
Agreement  between Investigator and Sponsor.  
15.13  Audit/Inspections  
To ensure compliance with relevant regulations, data generated by this registry  must be 
available for inspection upon request by representatives of Sponsor  and the IRB /EC for each 
investigational  site. 
 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
 
Reference s 
1 Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention 
of venous thromboembolism. N Engl J Med. 2009;360:1851 -1861.  
2 The surgeon general's call to action to prevent deep vein thrombosis and pulmonary 
embolism. U.S.  Department of Health and Human Services.  2008. Available at: 
www.surgeongeneral.gov/topics/deepvein/calltoaction/call -to-action -on-dvt-2008.pdf .  Acc essed 
11/30/08  
3 Piazza G, Fanikos J, Zayaruzny M, Goldhaber SZ. Venous thromboembolic events in 
hospitalised medical patients. Thromb Haemost.  2009;102:505 -510. 
4 Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the 
Intern ational Cooperative Pulmonary Embolism Registry (ICOPER). Lancet.  1999;353:1386 -
1389.  
5 Heit JA. The epidemiology of venous thromboembolism in the community: implications for 
prevention and management. J Thromb Thrombolysis.  2006;21:23 -29. 
6 Piazza G, Gold haber SZ. The acutely decompensated right ventricle: pathways for diagnosis 
and management. Chest.  2005;128:1836 -1852  
7 Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med.  
2011;364:351 -360. 
8 Piazza G, Goldhaber SZ. Management of submassive pulmonary embolism. Circulation.  
2010;122:1124 -1129.  
9 Kudo JS. Thrombolysis with ultrasound effect. Tokyo Jikeikai Med J 1989; 104:1005.  
10 Buldakov M,  Hassan a M, Zhao Q, Feril L, Kudo N, Kondo T, Litvyak ov N, Bolshako V, 
Cherdyntseva N, Riesz P.  Influence of changing pulse repetition frequency on chemical and 
biological effects induced by low -intensity ultrasound in vitro Ultrasonics Sonochemistry 16 
(2009) 392 –397 
11 Blinc A, Francis C, Trudnowski J, Car stensen E. Characterization of Ultrasound -Potentiated 
fibrinolysis In Vitro Blood 1993 81:2636 -2643  
12 Braaten JV, Goss RA, Francis CW. Ultrasound reversibly disaggregates fibrin fibers. Thromb 
Haemost.  1997;78:1063 -1068.  
13 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic 
medicinal products in non -surgical patients. J Thromb Haemost  2005; 3(4):692 -694 
14 EKOS received FDA 510k clearance in May 2014  
15 EKOS received CE Mark 567229 in  December 2010; recertified November 2015  
16 Clozel J P, et.al time course of thrombolysis induced by intravenous bolus or infusion of tissue 
plasminogen activator in a rabbit jugular vein thrombosis model Circulation 1989; 79:125 -133 
17 Eisenberg P R, et al . Sustained fibrinolysis after administration of t -PA despite its short half -
life in the circulation. Thrombosis and haemostasis 1987; 57:35 -40 
18 Verheugt F. Fibrinolytic Therapy in Clinical Practice. Martin Dunitz, London  2003 pg.6 -7 
 
Protocol BTG -001653 -01 (KNOCOUT PE)  
Version 2. 1 EMEA ( 19-Oct-2018)   
     
 EKOS Corporation  CONFIDENTIAL  
 A BTG International group company   
 
19 Lauer C G, et. al. Effect of ultrasound on tissue -type plasminogen activator -induced 
thrombolysis. Circ 1992; 86: 1257 -1264  
20 Chamsuddin A, et.al Catheter directed thrombolysis with the endowave system in the 
treatment of acute massive pulmo nary embolism: a retrospective multicenter case series. J 
Vasc Interv Radiol 2008; 19:372 –376 
21 Piazza, Gregory. “European Society of Cardiology.”  Echocardiographic Improvement after 
Short -Duration, Low -Dose TPA Regimens for Ultrasound -Facilitated, Cathete r-Based 
Fibrinolysis in Submassive PE: OPTALYSE -PE. 2017  
22 Tapson V., Sterling K., Jones N., et. al. “A Randomized Trial of the Optimum Duration of 
Acoustic Pulse Thrombolysis Procedure in Acute Intermediate -Risk Pulmonary Embolism:  The 
OPTALYSE PE Trial.” JACC Cardiovascular Interventions. Jul 2018, 11 (14) 1401 -1410; DOI: 
10.1016/j.jcin.2018.04.008.  
23 Piazza G, Goldhaber SZ. Management of submassive pulmonary embolism. Circulation. 
2010;122:1124 -1129  
24 Schulman S, Kearon C. Definition of major blee ding in clinical investigations of antihemostatic 
medicinal products in non -surgical patients. J Thromb Haemost  2005; 3(4): 692 -694 
 
 